Marcus & Millichap, Inc.
—- Market cap
- $1.21B
- Debt
- +$163.82M
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 88% equity / 12% debt
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MMI stock price at discount vs ALNY $31.89 current versus $191.18 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ALNY's multiple
Implied fair value · at MMI's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: MMI FY 2025 (ended Dec 31, 2025) · ALNY FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 88% equity / 12% debt
Capital structure 90% equity / 10% debt · EV / Revenue 10.25x · EV / EBITDA 63.81x
ALNY carries the larger enterprise value at $38.07B against $1.37B; MMI trades on the lower EV / Revenue multiple (1.82x vs 10.25x); ALNY on the lower EV / EBITDA (63.81x vs 87.93x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
MARCUS & MILLICHAP, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ALNYLAM PHARMACEUTICALS, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.27x
5.22x
Net debt / EBITDA
Leverage against operating earnings
—
4.13x
Cash and equivalents
Liquid reserves on the balance sheet
—
$1.66B
Total debt
Interest-bearing obligations outstanding
$163.82M
$4.12B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
CBRE GROUP, INC.
MMI vs CBRE
JONES LANG LASALLE INC
MMI vs JLL
Compass, Inc.
MMI vs COMP
AZEK Co Inc.
MMI vs AZEK
Moderna, Inc.
MMI vs MRNA
Sarepta Therapeutics, Inc.
MMI vs SRPT
VERTEX PHARMACEUTICALS INC / MA
MMI vs VRTX
BioNTech SE
MMI vs BNTX
ACADIA PHARMACEUTICALS INC
MMI vs ACAD
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.